AINewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) to Host July 28 Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski

Company: Fifty 1 Labs, Inc. (FITY)
Category: News

Fifty 1 Labs (OTC: FITY), a leader in AI-powered health and wellness solutions, announced it will host a virtual shareholder teleconference on Monday, July 28, 2025, at 12:00 PM EST. The event, streamed live on X (formerly Twitter), will feature Senior Scientist Dr. James Orbinski, who accepted the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières (Doctors Without Borders). The teleconference will highlight the company’s strategic roadmap for subsidiary Fifty 1 AI Labs, including AI-driven drug repurposing for functional medicine, a $1 million R&D investment, and plans for a $5–10 million biotech acquisition by 2027. Management underscored alignment with shareholders through $350,000 in personal investment and deferred salaries until a $50 million valuation or two-year horizon is reached. CEO Paul Arora said the company’s focus on off-patent drug repurposing and adaptive trials positions it for growth and global health impact.

To view the full press release, visit https://ibn.fm/pY49P

About Fifty 1 Labs, Inc.

Fifty 1 Labs, Inc. (OTC: FITY), a Nevada corporation based at 751 North Drive, Melbourne, FL 32934, is a holding company driving innovation in health, wellness, and biotechnology. FITY owns 100% of Genetic Networks LLC, a Delaware-based biotech firm founded in 2015 by Dr. Gennaro D’Urso. Genetic Networks, headquartered in Miami, Florida, develops the GeneScape™ platform, a yeast-based, whole-genome analysis tool that accelerates drug discovery for personalized medicine, biodefense, and wellness applications, with proven success serving major pharma clients like Bristol Myers Squibb. FITY also wholly owns 51, LLC, its sports nutrition subsidiary offering a premium line of supplements—including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies—designed to enhance athletic performance, recovery, and overall health. The Quickness, Astound NMN, and Drago Knives have been merged out of the company and are no longer part of Fifty 1 Labs, Inc., sharpening FITY’s focus on biotech and wellness synergies to empower individuals and organizations worldwide. For more information, visit the company’s website at https://fifty1labs.com/

About AINewsWire

AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.

AINW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit www.AINewsWire.com

Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer

AINewsWire
Austin, Texas
www.AINewsWire.com
512.354.7000 Office
Editor@AINewsWire.com

AINewsWire is powered by IBN